Bristol Myers Squibb's Growth Portfolio Now Brings In $7.7 Billion a Quarter. Here's Why That Changes the Stock's Story.

Bristol Myers Squibb is a large and well-respected drug maker. The company is facing the normal industry headwind of patent expirations.

TC Trade Conquest Newsroom November 14, 2026 ·1 min read

Key takeaways

Bristol Myers Squibb is facing down the expiration of patent protections for older drugs, but new drugs are starting to show promise.
In the third quarter of 2026, this collection of more than a dozen drugs generated revenues of $7.66 billion.
Right now, the legacy portfolio generates $5.42 billion in sales.

Bristol Myers Squibb is a large and well-respected drug maker. The company is facing the normal industry headwind of patent expirations.

See the latest quote, chart and news for BMY.

Want trade ideas like this in real time? Subscribe to Trade Conquest.